Hangzhou Tigermed Consulting Co., Ltd

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-05-18			5-day change	1st Jan Change
46.11 ^CNY	-1.39%		-12.00%	-18.68%

May. 13	Tigermed Consulting Launches 1 Billion Yuan Stock Buyback	MT
May. 13	Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	CI

Hangzhou Tigermed Consulting Co., Ltd Proposes Final Dividend for the Year Ended December 31, 2025, Payable on 31 July 2026

Published on 03/30/2026 at 05:06 am EDT

S&P Capital IQ

HANGZHOU TIGERMED CONSULTING CO., LTD

-1.39%

Hangzhou Tigermed Consulting Co. Ltd. proposed final dividend of RMB 1.26 per 10 share for the Year Ended December 31, 2025. Payment date is 31 July 2026.

Latest news about Hangzhou Tigermed Consulting Co., Ltd

May. 13	Tigermed Consulting Launches 1 Billion Yuan Stock Buyback	MT
May. 13	Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	CI
May. 13	Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	CI
May. 13	Hangzhou Tigermed Consulting clarifies 2 controlling shareholders made corresponding announcements on all previous reduction of shareholding	RE
May. 13	Hangzhou Tigermed Consulting plans to buy back co A-shares	RE
May. 13	HBM Holdings says independent non-executive director receives case filing notice from CSRC	RE
May. 12	Tigermed Consulting Stock Tumbles as Directors Face Regulatory Probe	MT
May. 12	Hangzhou Tigermed Consulting's actual controllers under investigation by securities regulator	RE
Apr. 28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 28	Tigermed Consulting's Q1 Profit Slides 70%	MT
Apr. 28	Hangzhou Tigermed Consulting Q1 net profit down 70.4% Y/Y	RE
Mar. 31	Jefferies Adjusts Hangzhou Tigermed Consulting's Price Target to 65 Yuan From 80 Yuan, Keeps at Buy	MT
Mar. 31	Jefferies Adjusts Hangzhou Tigermed Consulting's Price Target to HK$55 From HK$50, Keeps at Buy	MT
Mar. 30	Tigermed announces 2025 annual results	RE
Mar. 30	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Chart Hangzhou Tigermed Consulting Co., Ltd

Duration

Period

Chart Hangzhou Tigermed Consulting Co., Ltd

300347: Dynamic Chart

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Employees

11,130

Sector

Biotechnology & Medical Research

More about the company